- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Supernus Pharmaceuticals CEO Sells $1.76M in Stock
Insider sale trims CEO's stake by 3.52% as analyst coverage remains mixed
Mar. 17, 2026 at 8:19am
Got story updates? Submit your updates here. ›
Supernus Pharmaceuticals CEO Jack Khattar sold 35,000 shares of the company's stock on March 13 at an average price of $50.37, for a total of $1,762,950. This transaction reduced Khattar's stake in the company by 3.52% to 958,100 shares, worth approximately $48.26 million. Analyst coverage of Supernus Pharmaceuticals is mixed, with four Buy ratings, one Hold, and two Sell ratings, resulting in an average rating of Hold and a consensus target price of $62.17.
Why it matters
The insider sale by the CEO of Supernus Pharmaceuticals is noteworthy as it represents a significant reduction in his personal stake in the company. Insider transactions can provide insights into management's views on the company's prospects and valuation. The mixed analyst coverage and target price also suggest there is some uncertainty around the stock's future performance.
The details
Supernus Pharmaceuticals CEO Jack Khattar sold 35,000 shares of the company's stock on March 13 at an average price of $50.37, for a total transaction value of $1,762,950. This sale reduced Khattar's ownership stake in the company by 3.52%, from 993,100 shares to 958,100 shares, which are currently valued at approximately $48.26 million.
- The stock sale occurred on March 13, 2026.
The players
Jack Khattar
The CEO of Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.
A specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The insider sale by Supernus Pharmaceuticals' CEO, combined with the mixed analyst coverage, suggests there may be some uncertainty around the company's future performance and valuation. Investors will likely be closely monitoring the stock's movements and any further developments related to the company's leadership and strategic direction.
